TITLE

Financings Roundup

PUB. DATE
September 2007
SOURCE
BioWorld Today;9/21/2007, Vol. 18 Issue 184, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that ThromboGenics NV strengthened its cash position by &euro5.1 million through the exercise of 1.1 million pledges. It is stated that the company's number of outstanding shares increased to 25.5 million. ThromboGenics has various programs in the clinic which is in Phase II testing for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, and TB-402 (anti-Factor VIII), which is set to enter a Phase II study next year in partnership with Bioinvent International AB, of Lund, Sweden.
ACCESSION #
26714861

 

Related Articles

  • ThromboGenics Stock Sky High on Microplasmin Phase III Data. Sheridan, Cormac // BioWorld International;4/21/2010, Vol. 15 Issue 16, p1 

    The article reports on the stock gains posted by ThromboGenics NV in April 2010 following disclosure that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). A brief...

  • Thrombogenics' Clot-Busting Drug Moves into Phase III. Nuala, Moran // BioWorld International;2/9/2011, Vol. 16 Issue 6, p2 

    The article focuses on the Phase III trial for the THR-100 staphylokinase clot-busting drug of Thrombogenics NV. It is expected to be completed in 2011, leading to a launch that could coincide with the approval of microplasmin for the treatment of symptomatic focal vitreomacular adhesion. The...

  • ThromboGenics Stock Climbs on Microplasmin Phase III Data. Sheridan, Cormac // BioWorld Today;4/21/2010, Vol. 21 Issue 76, p1 

    The article reports that shares in ThromboGenics NV reached its highest price at 18.80 euros following news that its lead drug candidate microplasmin posted good results in the first of two Phase III trials for treating symptomatic focal vitreomacular adhesion (VMA). The trial, which involved...

  • ThromboGenics Stock Up on Microplasmin Data.  // Bioworld Week;4/26/2010, Vol. 18 Issue 17, p4 

    The article reports that ThromboGenics NV's traded shares have reached an all-time high during its early trading on April 20, 2010 in view of the success of the Phase III trials of its lead drug microplasmin for the treatment of symptomatic focal vitreomacular adhesion (VMA).

  • Financings Roundup.  // BioWorld Today;10/12/2009, Vol. 20 Issue 196, p3 

    The article reports on the funds raised by ThomboGenics NV of Leuven, Belgium from the exercise of warrants by several of the company's employees. The company has nearly 26.4 million shares outstanding. The company is currently developing microplasmin for the nonsurgical treatment of...

  • Does Rush of New Money Mean the Financial Tide has Turned? Sheridan, Cormac // BioWorld International;11/18/2009, Vol. 14 Issue 46, p1 

    The article reports on an increase in activity by investors in biotechnology stocks in Europe. Martinsried, Germany-based 4SC AG was able to secure 30 million euros in a combined rights issue and private placement, while Leuven, Belgium-based Thrombogenics NV completed a funding round worth 42...

  • ThromboGenics completes enrollment for phase 3 MIVI-TRUST program.  // Ocular Surgery News;1/25/2010, Vol. 28 Issue 2, p38 

    The article reports on the completion of enrollment by ThromboGenics for the second of two phase 3 trials involved in its MIVI-TRUST clinical program in 2010. The aim of the program is to determine microplasmin for the non-surgical treatment of focal vitreomacular adhesion. The randomized,...

  • Affymax Raising $42M for Hematide Trials.  // Bioworld Week;2/23/2009, Vol. 17 Issue 8, p3 

    The article reports on the aim of Affymax Inc. in Palo Alto, California to raise $42 million in its four Phase III trials of Hematide. It states that the fund will be coming from the sale of 2.8 million shares priced at $11.25 each. Also, the firm plans to sell 652,262 units for $15.33 apiece....

  • MAP Relieves Cash Headache: $30M to Fund Migraine Trials. Hollingsworth, Catherine // BioWorld Today;8/7/2009, Vol. 20 Issue 151, p1 

    The article reports on the planned stock offering of MAP Pharmaceuticals Inc. The Mountain View, California-based company is looking to raise a minimum of 30 million U.S. dollars from its offering, pricing shares at 9.70 U.S. dollars. The company is also focused on conducting a Phase III trial...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics